Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

RELPAX 40MG TABLET - SFDA Drug Approval Details

Approvals/SFDA/RELPAX 40MG TABLET

Authorized

NCE

RELPAX 40MG TABLET

Unknown🇸🇦 Saudi Food and Drug Authority

Approval Date: N/A
Approval ID: 665f965bf909aa3f
Company: Unknown
Type: NCE

Approval Details

Approval Id: 665f965bf909aa3f
Drug Approval Sfda Name: RELPAX 40MG TABLET
Trade Name: RELPAX 40MG TABLET
Generic Name: ELETRIPTAN
Register Number: 2305233705
Register Year: 2017
Drug Type: NCE
Route Of Administration: Oral use
Package Type: Blister
Package Size: 6
Legal Status: Prescription
Authorization Status: Valid
Marketing Status: Marketed
Product Control: Uncontrolled
Storage Conditions: store below 25°c
Shelf Life: 36 Months
Distribution Site: Pharmacy
Description Code: 7000000442-40-100000073665
Price: 84.83

Active Ingredients

Authorized

Quick Info

Agency

SFDA

Country

🇸🇦

Approval ID

665f965bf909aa3f

Type

NCE

Back to SFDA Approvals